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This consensus statement is an up-date of the previous European
guideline from 2008 and relates to colposcopy undertaken in patients
identified through cervical screening and does not deal with the organ-
isation and management of cervical screening itself [1].
⁎ Corresponding author at: Aberdeen Centre for Women’s Health Research, Aberdeen
Maternity Hospital, Aberdeen, AB25 2ZD, UK.
Email address: m.e.cruickshank@abdn.ac.uk (M.E. Cruickshank)
The guidance is intended for general, rather than specialist or ex-
pert colposcopists and therefore may not be appropriate in countries
such as the United Kingdom or Germany where such distinctions do
not exist. Although there are some differences in colposcopic practice
in different parts of Europe, this statement aims to a common con-
sensus or core of practise. This guidance provides a short but not ex-
haustive set of recommendations that will cover most aspects of col-
poscopy. Specialist advice should be sought for those topics not ade-
quately covered, either because of complexity or lack of consensus.
In 2018, cervical cancer is still a major health issue in Europe
with 61.072 diagnoses and 25.829 deaths [2]. It is with a crude in-
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women per year, the second most common disease and cause of death
in women aged between 15–44 years in Europe [2]. Primary (vacci-
nation) and secondary prevention (screening) have the potential to re-
duce the world-wide cervical cancer incidence to 4 or less per 100.000
by the end of the century [3].
The World Health Organisation has called for urgent action to
scale up implementation of proven measures towards achieving the
elimination of cervical cancer as a global public health problem, in-
cluding vaccination against HPV, screening and treatment of pre-can-
cer, early detection and prompt treatment of early invasive cancers,
and palliative care [3].
Colposcopy is a tool to evaluate women who have an abnormal
cervical screening test (including cytology and HPV tests) or to assess
women with a clinically suspicious cervix.
Women who have a positive cervical screening result are at risk of
having a progressive cervical neoplastic lesion, which without treat-
ment might progress to cancer. Equally some lesions may regress
spontaneously, especially in young women, and therefore treatment
can be avoided. Criteria for referral to colposcopy will vary between
different cervical screening programmes for a variety of reasons. Like-
wise, patients are informed differently about colposcopy.
An overview of digital information leaflets for colposcopy avail-
able in European countries, together with the EFC consensus leaflet
for women attending a colposcopy clinic are shown respectively in
Tables 1 and 2.
The aims of colposcopy are:
1 To evaluate the cervical, vaginal, vulvar and perianal epithelium
and to differentiate between normal and abnormal.
2 To determine the precise geographical/anatomical position of the
cervical transformation zone (TZ).
3 To identify if there are atypical findings in squamous epithelium
and enable appropriate histological assessment.
4 To recognize or rule out cervical glandular disease.
Table 1








































EFC consensus leaflet for women attending a colposcopy clinic.
What is colposcopy?
A colposcopy is an examination to check the health of your cervix (neck of the
womb).
A specialist doctor (called a colposcopist) looks at your cervix using a colposcope.
This looks like a pair of binoculars on a stand. It does not go inside you.
Why do I need a colposcopy?
• Your cervical screening test has shown that the human papillomavirus (HPV) is
present, which can cause cell changes; or
• You have had symptoms of bleeding after sex or between your period
• You cervix showed some alteration and your doctor wanted you to have a
closer examination of your cervix
What does ‘cell changes’ mean?
Your smear sample may be checked for HPV virus as well as for changes in the
cells that covers the cervix. If changes are seen in the cells taken at your
screening test, there is a chance they will need to be treated.
Most ‘low grade’ changes do not need treating, but your colposcopist needs to see
you to make sure.
If you have ‘high grade’ changes, these might need to be treated, to stop them
becoming cervical cancer. Most women who have a colposcopy do not have
cervical cancer.
What is HPV?
The human papilloma virus (HPV) is a common virus. Today, more than 200
different types of HPV are known. Of these, at least 40 can cause genital
infection and 13 of these 40 are high-risk HPV types with the ability to cause
cervical precursor changes and cancer. According to studies, more than 80 % of
people have had a papillomavirus infection in their lifetime.
There is no medical treatment for an HPV infection. This virus infection itself is
not cancer or any of its preliminary stages; yet HPV is a necessary factor in the
development of precancer stages in the cervix. These premalignant lesions can
be effectively treated. In non-serious cases, monitoring through Pap tests is
sufficient, since most of these changes and infections heal on their own.
What will happen at the clinic?
The colposcopist will explain why you are at the clinic and what they will do. You
can ask them any questions. It is helpful to know the date of your last period.
The colposcopist will check if you are happy to go ahead with the examination.
What happens during the colposcopy examination?
You will need to get onto a special couch. A nurse will help you and stay with you.
A speculum (the same instrument used when you had your smear taken) is
gently put inside your vagina. The colposcopist will put some liquid onto your
cervix. Sometimes this can feel cold or can tingle. Most colposcopists use a
combination of diluted acetic acid and Schiller’s iodine tests:
Acetic acid is a very weak acidic liquid. It is sometimes called diluted vinegar. The
colposcopist gently applies it to your cervix using a cotton wool ball or with a
spray. It shows cell changes by turning them white.
Schiller's iodine test uses an iodine solution. It stains normal cervical tissue dark
brown. Cell changes may not stain, so the colposcopist can see them. Some
people are allergic to iodine or sea food. If you are, please tell your colposcopist
The colposcopist might take a small piece of skin from your cervix for a biopsy
(examination) if they think there are cell changes. This is sometimes called a
punch biopsy. You will be contacted with your results. These will confirm if
you need treatment or not.
The examination takes 10−20min.
What about treatment?
You may be offered treatment at your first visit, if you have high grade changes
and if you agree, to get rid of cell changes. This will be explained to you at the
time. There are different ways of treating cell changes. You may have heard of
‘loop treatment’ as this is the commonest way of treating CIN today. The full
name for the procedure is ‘Large Loop Excision of the Transformation Zone’ or
LLETZ. The abnormal area is removed using a wire loop through which an
electric current is passed. This can be performed after you are given local
anaesthetic to ‘numb’ the cervix. LLETZ is a simple and safe technique which
gives excellent results. Very few women may need a general anaesthetic and
you will discuss this with your colposcopist.
Another form of treatment is ablation which destroys the abnormal cells. If you
have ablation, you will have a punch biopsy first and return for treatment under
local anaesthetic.
You will not need sick leave or pain medication after treatment. Minor mucous,
bloody discharge will occur following the procedure for a few weeks. Taking a
bath, swimming and having sexual intercourse are not recommended for 4
weeks due to a risk of inflammation and discharge. Some this there is an odour,
if so contact your doctor.
Cervical cytological changes or their possible treatment do not cause infertility.
Recent studies show that LLETZ-treatment may slightly increase the risk of
preterm delivery.
Not all cell changes need to be treated. Cell changes are usually treated if they do
not go back to normal or are more than low-grade changes.
Treatment is nearly always successful. A small number of women might need to be
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What else do I need to know?
If you are having your period on the day of your appointment, please ring the
clinic. They may tell you to keep your appointment, especially if your periods
are not regular.
A colposcopy can be done safely during pregnancy. If you need treatment this is
usually delayed until three months after your baby is born.
If you have a coil (IUD) there is a small chance that it might need to be taken out
at your appointment. If the coil is removed install a new one or check the risk of
pregnancy.
What if I have problems after the colposcopy?
Please contact the clinic or follow the advice the colposcopy clinic gave you, if
you notice:
• heavy bleeding (not your period)
• vaginal discharge with or without an odour that is not normal for you
• pain that doesn’t get better with your usual painkillers
• that you feel hot and cold, or shivery
5 To recognize or rule out invasive cancer.
6 To facilitate treatment of intra-epithelial lesions. Colposcopy must
be systematically performed prior to treatment of suspected or con-
firmed intra-epithelial disease
7 To monitor progression or regression of intra-epithelial lesions.
Conduct of colposcopy:
1 Colposcopy should only be performed by trained, and preferably
certified, colposcopists or by trainees under appropriate supervi-
sion.
2 Every woman should be offered verbal information during col-
poscopy and be sent written information before colposcopy to facil-
itate informed consent.
Technique of colposcopy
Colposcopy is a diagnostic procedure to visualize the epithelia of
the lower genital tract with magnification and adequate illumination
before and after application of acetic acid and Lugol´s iodine.
The colposcopic examination should be adequately documented,
using the International Federation of Cervical Pathology and Col-
poscopy (IFCPC) nomenclature [4] (See Table 3). The Swede Score
[5] can be helpful to evaluate lesion grade and guide appropriate man-
agement (See Table 4).
Colposcopically directed punch biopsies:
• Should provide interpretable material
• Sensitivity is improved if at least two are taken
• Are not representative when there is a TZ 3
• LSIL cytology and grade 1 or negative colposcopic findings do not
require biopsies in every case, but are recommended [6,7]
• Reasons for not performing a biopsy should be recorded
• If biopsies are reported as inadequate, then biopsy should be re-
peated if there is a residual colposcopic lesion.
Excisional biopsy such as Large Loop Excision of the Transforma-
tion Zone (LLETZ) is recommended in the following circumstances:
• When invasion is suspected colposcopically
• When the squamo-columnar junction (SCJ) is not visible (TZ 3) but
histology is required.
An excisional biopsy/LLETZ can be considered when there is
HSIL cytology and colposcopic grade 2 findings
Endocervical curettage can be considered:
• When the SCJ is not visible but histology is required
• When glandular disease is suspected.
Table 3
Documentation of a colposcopic examination; IFCPC 2011 colposcopic terminology of
the cervix (4).
2011 IFCPC colposcopic terminology of the cervix1
General assessment • Adequate/inadequate for the reason ….. (i.e.:
cervix obscured by inflammation, bleeding,
scar)
• Squamo-columnar junction visibility: com-
pletely visible, partially visible, not visible

















Location of the lesion: Inside or outside the T-
zone, Location of the lesion by clock position
Size of the lesion: Number of cervical quadrants























Leukoplakia (keratosis, hyperkeratosis), Erosion,
Lugol’s staining (Schiller’s test): stained/non-
stained
Suspicious for invasion Atypical vessels
Additional signs: Fragile vessels, Irregular














Colposcopy in postmenopausal women:
• Colposcopic examination and adequacy can be improved from the
use of topical hormone replacement therapy.
Colposcopy in pregnancy:
• Should only be undertaken by an experienced, trained colposcopist
• Should be performed, if indicated, and not deferred because of preg-
nancy
• Primarily aims to detect or exclude invasive disease. If invasive dis-
ease is not suspected, then punch biopsy or treatment is deferred un-
til post-partum
• Should not include endocervical curettage
• Enables excisional biopsy/ LLETZ if invasion is suspected
• If colposcopy has been performed for an abnormal cytology or
biopsy-proven CIN during pregnancy, postpartum assessment is es-
sential.
Management and treatment
Cervical screening aims to reduce cervical cancer incidence and
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Table 4
The Swede score and interpretation of total score.
Swede Score
0 1 2 Score






















Lesion size <5mm 5−15mm or 2
quadrants




Iodine staining Brown Faintly or
patchy yellow
Distinct yellow
Total score (maximum 10)
Interpretation of Swede Score
Overall Swede Score Colposcopic prediction of probable histology
0–4 Low grade/normal
CIN 1
5–6 High grade/non invasive cancer
CIN 2+
7–10 High grade/suspected invasive cancer
CIN 2+
of treatment is to remove or ablate the premalignant epithelium in its
entirety.
When to treat:
• When HSIL confirmed histologically or highly probable on basis of
cytology and colposcopic findings. Treatment of histological LSIL
should be avoided
• Not every non-pregnant woman with a histological HSIL needs
treatment. Expectant management can be considered, if women are
young (aged <30), have small HSIL/CIN2 lesions with a completely
visualised TZ and can be carefully monitored [8]
• The woman should be adequately counselled, and consent obtained.
Treatment methods:
1 All women needing treatment must have had a colposcopic assess-
ment
2 Treatment modalities for histological HSIL include local treatments
(excision or ablation) and, rarely, hysterectomy
3 There is no obviously superior conservative technique for treating
SIL [9]
4 Ablative techniques are only suitable when:
• The entire TZ is visualised
• There is no evidence of glandular abnormality
• There is no evidence of invasive disease
• There is an established histological diagnosis
• There is no major discrepancy between cytology and histology
• There has been no previous treatment
5 Cryocautery should not be used to treat HSIL.
Methodology
• Local treatments should be performed, wherever possible, in outpa-
tients and with local analgesia
• The treatment should be done using a colposcope
• Treatment at first visit to colposcopy with ASCUS or LSIL cytol-
ogy should not be offered
• Excisional treatments should aim for complete excision of CIN
• Excisional treatments should have a length of at least 8mm
(NHSCSP, 2016) and be tailored to the size of the cervix and TZ
status.
Initial management of women with ASCUS
Women with ASCUS can be referred to colposcopy in one of a
number of scenarios, depending on the agreed arrangements in that
screening programme. Referral after a single ASCUS result is felt to
be sub-optimal. Indications for colposcopy include:
• If reflex high-risk HPV (hrHPV) testing is positive
• Persistent cytological abnormality on follow up.
Management is dependent on findings:
• If colposcopy is normal, and the TZ completely visualised, then the
woman can return to recall
• If grade 1 abnormalities are observed, colposcopic biopsy is not
mandatory but often recommended to confirm or exclude CIN. If
not biopsied then a further cervical test (e.g. cytology +/- hrHPV)
should be performed in 12 months
• If there is biopsy-proven histological LSIL lesion, a repeat cervical
test (cytology +/− hrHPV test) should be performed in 12 months
• If the lesion has not resolved within 2 years of initial referral to col-
poscopy, then a biopsy should be taken
• If there are grade 2 changes then biopsy is mandatory.
Initial management of women with LSIL
Women with LSIL can be referred to colposcopy in one of a num-
ber of scenarios, depending on the agreed arrangements in that screen-
ing program. These include:
• Direct referral to colposcopy after a single LSIL result
• When hrHPV test is positive
• Persistent cytological abnormality on follow-up.
Colposcopic management and follow-up is as for ASCUS.
Initial management of women with HSIL
Biopsies should be taken in non-pregnant women.
• If histological HSIL is confirmed, then treatment should usually be
performed but expectant management can be considered in young
women (<30 years) with a small area HSIL/CIN 2 lesion, with a
fully visible transformation zone [9]
• If treatment is not undertaken, then close surveillance with col-
poscopy and cytology is recommended with 6 monthly intervals. If
at follow-up HSIL cytology persists over 24 months, then excisional
treatment is recommended
• If HSIL cytology cannot be explained on biopsy and vaginal in-
traepithelial neoplasia has been excluded, then such cases should be
discussed at multidisciplinary meetings. Multiple directed biopsies
or loop excision should have been taken. If histological LSIL or less
is confirmed, then colposcopic follow-up with cytology and biop-
sies at 6 months is recommended
• If invasion is suspected at colposcopy, then an excisional biopsy/
LLETZ is indicated. If cancer is confirmed on histology, then the
case should be reviewed in a gynaecological oncology unit.
Management of women with glandular abnormalities
• Expert cytological and colposcopic assessment is essential. Women
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Follow-up after treatment for CIN
Follow-up after treatment is essential as treated women are be-
tween two to five times more likely to develop cervical cancer in at
least the next 20 years. The following are recommended:
• hrHPV testing at 6 months (test of cure, TOC), either alone or in
conjunction with cytology is recommended [2,10]
• Women with a cytological sample that has been reported as nega-
tive or as showing LSIL or less and whose hrHPV test is negative
should be recalled in 3 years
• Women with a cytological sample that has been reported as nega-
tive or as showing LSIL or less and whose hrHPV test is positive
should be referred for colposcopy
• Women with a HSIL, ASC-H or AGC cytology should be referred
to colposcopy.
Follow-up of following treatment for early stage cervical cancer
In these cases, follow-up is likely to be determined by the man-
agement policy of the treating gynaecological oncologist. In general
terms, if conservative treatment has been performed, leaving a resid-
ual cervix, then regular long-term follow-up with cytology follow-up
or hrHPV testing is recommended.
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